Capricor Therapeutics 주식 (NASDAQ: CAPR)

에 대한 최신 뉴스 Capricor Therapeutics (NASDAQ:CAPR) 주식

Capricor Therapeutics

Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.

Equities

News

Markets

BABA

CAPR

NVDA

TSLA

화요일에 주요 미국 지수들이 상승했다. 다우존스 산업평균지수가 0.2% 상승하여 42,208.22에, S&amp;P 500이 0.25% 상승하여 5,732.93에, 나스닥이 0.6% 상승하여 18,074.52에 장을 마쳤다.

화요일 주목받은 주식 5종목: 엔비디아, 알리바바, 카프리코, TSMC 그리고 테슬라

Capricor Therapeutics, Inc. - Common Stock

Capricor Therapeutics Inc

CAPRAL LTD by Capral Ltd.

Capri Holdings Ltd

CAPRICORN ENRGY U/ADR by CAPRICORN ENERGY PLC

Capricorn Energy PLC

CAPRICORN ENERGY PLC by CAPRICORN ENERGY PLC

Capricorn Energy PLC ADR

CAPRICORN METALS LTD by CAPRICORN METALS LTD.

Capricorn Metals Ltd

<a href="https://www.globenewswire.com/Tracker?data=k2oa82HEGM__3Yzz0yJvsZzMMnTe1Nym8talO1eUxwUyYJdtkvI-bRDFNKmjf7ctRJJCpB78oCVassCvXaxxsKablw3_gXDHr2o5dvWwxZQ=">Capricor Therapeutics</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the European Medicines Agency (EMA) has granted both <a href="https://www.globenewswire.com/Tracker?data=eY5qvZgML1l0T8WtNLW5t18Cs8VDTy3DJB9QjH5LGdFCt3JyModJoo3s-cthbj9cbd_VSyIjhwaC2XMv3pVSNnTmfd8sYzTW_gRcla3QwSo4QkBs6XYRocH6Xf4BozQsfu4GHtniI9EOI-N4LGmf3Wv_MfEbp5so13EgePZhxc8=">Orphan Drug</a> and <a href="https://www.globenewswire.com/Tracker?data=-arUOacIGoO6Td1LTLGgqohl6j7PTdGAS0N0xloS2tq5BRmbC2mKPafXn6kJCeAUpPeRIFh0Pt1nvB4xNpndGrjAi5PFlfMYc5lZqcBhKgOFvI2PddtRwX-msbJtcodYxS9dSVO0o7BKpYa82cyJuYOmEJHy8F564jH8hcQ-AmaMmXH_UZD7fg5kTxXo2PzBEDcO3nK_MVYi4_Xz4gmb1A==">Advanced Therapy Medicinal Product</a> (ATMP) designations to its lead asset, deramiocel, for the treatment of Duchenne muscular dystrophy (DMD).
The Orphan Drug designation provides Capricor with several benefits that support the development of deramiocel in Europe, including market exclusivity for 10 years if approval is granted and substantially reduced regulatory fees.&nbsp;The ATMP designation provides substantial regulatory support to assist in the development of cell-based therapies. The additional support can potentially reduce time to market, streamline development, and open up access to critical resources, making it an invaluable tool for companies working on innovative therapies.

Biotech

Global

General

Capricor Therapeutics Granted Orphan Drug And ATMP Status For Deramiocel By EMA

Jones Trading analyst Catherine Novack initiates coverage on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy rating and announces Price Target of $40.

Price Target

Initiation

Analyst Ratings

Jones Trading Initiates Coverage On Capricor Therapeutics with Buy Rating, Announces Price Target of $40

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Buy and maintains $77 price target.

Reiteration

HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $77 Price Target

WIIM

Capricor Therapeutics shares are trading higher after Cantor Fitzgerald maintained an Overweight rating on the stock and raised its price target from $25 to $30.

Analysts' ratings for Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) over the last quarter vary from bullish to bearish, as provided by 12 analysts.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">6</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Capricor Therapeutics, revealing an average target of $31.67, a high estimate of $77.00, and a low estimate of $8.00. Observing a 33.46% increase, the current average has risen from the previous average price target of $23.73. 
<img src="https://www.benzinga.com/files/images/story/2024/1731592835_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The perception of Capricor Therapeutics by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Edward Tenthoff</td>
<td>Piper Sandler</td>
<td>Announces</td>
<td>Overweight</td>
<td>$35.00</td>
<td>-</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$77.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Raises</td>
<td>Buy</td>
<td>$25.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$8.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>Leland Gershell</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$15.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Jason McCarthy</td>
<td>Maxim Group</td>
<td>Maintains</td>
<td>Buy</td>
<td>$12.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$40.00</td>
<td>$40.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Capricor Therapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Capricor Therapeutics compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Capricor Therapeutics's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Capricor Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Capricor Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Get to Know Capricor Therapeutics Better</h2>
Capricor Therapeutics Inc is a biotechnology company focused on advancing transformative cell and exosome-based therapeutics to redefine the treatment landscape for rare diseases. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat and prevent a wide range of diseases with targeted delivery.
<h3>Financial Milestones: Capricor Therapeutics's Journey</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Over the 3 months period, Capricor Therapeutics showcased positive performance, achieving a revenue growth rate of 1.38% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Capricor Therapeutics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -276.97%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Capricor Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -73.49%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Capricor Therapeutics's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -25.08%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.16, Capricor Therapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Decoding 12 Analyst Evaluations For Capricor Therapeutics

Cantor Fitzgerald analyst Kristen Kluska maintains Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight and raises the price target from $25 to $30.

Cantor Fitzgerald Maintains Overweight on Capricor Therapeutics, Raises Price Target to $30

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) reported quarterly losses of $(0.38) per share which missed the analyst consensus estimate of $(0.36) by 5.56 percent. The company reported quarterly sales of $2.30 million which missed the analyst consensus estimate of $3.57 million by 35.54 percent. This is a 62.81 percent decrease over sales of $6.18 million the same period last year.

Earnings

Earnings Misses

Capricor Therapeutics Q3 2024 GAAP EPS $(0.38) Misses $(0.36) Estimate, Sales $2.30M Miss $3.57M Estimate

ACXP

ADAP

AEMD

AFCG

AFYA

AGRO

AIRJ

ALUR

ALVO

ARCO

ATEX

AYTU

BCDA

BETR

BFRI

BITF

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNGO

BOXL

BRFS

BWEN

CAAS

CREX

CRNT

CSAN

CSCO

CSLR

CSTE

CYBR

DADA

DGII

DMAC

DOLE

DRRX

DTCK

ECOR

EDBL

ENLT

EZPW

FORA

FPAY

FULC

GILT

GLAD

GOEV

GRYP

HIVE

HROW

HYZN

IBTA

ICAD

ICCC

INLX

INVZ

JAGX

JJSF

KBDC

KLIC

KMDA

KRMD

KULR

LMFA

LOAR

LQDA

LUCD

LVLU

MCRB

MPTI

MRSN

NTWK

NXGL

OMER

OPRX

OTRK

OWLT

OXBR

PAVM

PCYO

Earnings Scheduled For November 13, 2024

Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) is gearing up to announce its quarterly earnings on Wednesday, 2024-11-13. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Capricor Therapeutics will report an earnings per share (EPS) of $-0.36.
Investors in Capricor Therapeutics are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.01, leading to a 8.99% increase in the share price on the subsequent day.
Here's a look at Capricor Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.36</td>
<td>-0.11</td>
<td>-0.09</td>
<td>-0.29</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.35</td>
<td>-0.31</td>
<td>-0.02</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>-4.0%</td>
<td>9.0%</td>
<td>7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1731420166_0.png" alt="eps graph" />
<h3>Performance of Capricor Therapeutics Shares</h3>
Shares of Capricor Therapeutics were trading at $19.54 as of November 11. Over the last 52-week period, shares are up 508.72%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CAPR/earnings">To track all earnings releases for Capricor Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Capricor Therapeutics

Deep-pocketed investors have adopted a bearish approach towards Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in CAPR usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 11 extraordinary options activities for Capricor Therapeutics. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 27% leaning bullish and 54% bearish. Among these notable options, 3 are puts, totaling $146,410, and 8 are calls, amounting to $463,700.
<h3>What's The Price Target?</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $5.0 to $30.0 for Capricor Therapeutics over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Capricor Therapeutics's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Capricor Therapeutics's whale activity within a strike price range from $5.0 to $30.0 in the last 30 days. 
<h3>Capricor Therapeutics Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729714523_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$16.5</td>
<td>$15.7</td>
<td>$15.9</td>
<td>$5.00</td>
<td>$111.3K</td>
<td style="text-align: right;">803</td>
<td style="text-align: right;">70</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$16.6</td>
<td>$16.0</td>
<td>$16.3</td>
<td>$5.00</td>
<td>$81.5K</td>
<td style="text-align: right;">803</td>
<td style="text-align: right;">120</td>
</tr>
<tr>
<td>CAPR</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$15.6</td>
<td>$14.2</td>
<td>$15.22</td>
<td>$30.00</td>
<td>$76.1K</td>
<td style="text-align: right;">58</td>
<td style="text-align: right;">50</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$25.00</td>
<td>$72.1K</td>
<td style="text-align: right;">216</td>
<td style="text-align: right;">250</td>
</tr>
<tr>
<td>CAPR</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$3.5</td>
<td>$3.4</td>
<td>$3.5</td>
<td>$25.00</td>
<td>$55.3K</td>
<td style="text-align: right;">216</td>
<td style="text-align: right;">158</td>
</tr>
</tbody>
</table>

<h3>About Capricor Therapeutics</h3>
Capricor Therapeutics Inc is a United States-based biotechnology company focused on the discovery, development, and commercialization of first-in-class biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy and other medical conditions. The company's development stage product pipeline includes CAP-1002, for Duchenne Muscular Dystrophy Program and COVID-19 Program; CDC-Exosomes (CAP-2003); and Exosome-mRNA vaccine.
After a thorough review of the options trading surrounding Capricor Therapeutics, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Capricor Therapeutics's Current Market Status</h3>
<ul>
<li>With a volume of 1,798,587, the price of CAPR is up 5.46% at $21.24. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 20 days.</li>
</ul>
<h3>Professional Analyst Ratings for Capricor Therapeutics</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $44.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; In a cautious move, an analyst from Piper Sandler downgraded its rating to Overweight, setting a price target of $35. 
&#x2A; An analyst from HC Wainwright &amp; Co. has decided to maintain their Buy rating on Capricor Therapeutics, which currently sits at a price target of $77. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $40. 
&#x2A; An analyst from Maxim Group has decided to maintain their Buy rating on Capricor Therapeutics, which currently sits at a price target of $25. 
&#x2A; Maintaining their stance, an analyst from Oppenheimer continues to hold a Outperform rating for Capricor Therapeutics, targeting a price of $43. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Capricor Therapeutics with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Capricor Therapeutics Options Trading: A Deep Dive into Market Sentiment

Capricor Therapeutics shares are trading higher after Piper Sandler initiated coverage on the stock with an Overweight rating and announced a price target of $35.

Piper Sandler analyst Edward Tenthoff initiates coverage on Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) with a Overweight rating and announces Price Target of $35.

Piper Sandler Initiates Coverage On Capricor Therapeutics with Overweight Rating, Announces Price Target of $35

Capricor Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares are trading lower by 6.05% to $19.27 during Thursday&#8217;s session. The company earlier commenced its <a href="https://www.benzinga.com/pressreleases/24/10/g41375519/capricor-therapeutics-announces-pricing-of-approximately-75-million-public-offering-of-common-stoc">public offering of common stock</a>.
What To Know: The company announced the pricing of its public offering of 4.41 million shares at $17.00 per share. The company granted underwriters a 30-day option to purchase an additional 661,800 shares. 
The offering, expected to close on October 18, will raise approximately $75 million before expenses and commissions. 
Piper Sandler &amp; Co. and Oppenheimer &amp; Co. Inc. are managing the offering. Capricor says the company plans to use the funds for product development, manufacturing, working capital, and general corporate purposes.
Stock Of The Day: <a href="https://www.benzinga.com/trading-ideas/technicals/24/10/41383732/stock-of-the-day-taiwan-semiconductor-breaks-out-as-buyers-push-prices-higher">Taiwan Semiconductor Breaks Out As Buyers Push Prices Higher</a>
<h2 class="wp-block-heading">Should I Sell My CAPR Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. Capricor Therapeutics stock currently has an RSI of 61.26, indicating neutral conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>

Why Capricor Therapeutics (CAPR) Shares Are Trading Lower

U.S. stock futures were mostly higher this morning, with the Nasdaq futures gaining around 100 points on Thursday.
Shares of CSX Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSX#NASDAQ">CSX</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41369567/csx-stock-falls-after-worse-than-expected-q3-results-details">third-quarter earnings below analyst estimates.</a>
CSX reported quarterly GAAP earnings of 46 cents per share, which missed the consensus estimate of 48 cents per share. Quarterly revenue came in at $3.62 billion, also missing the consensus estimate of $3.676 billion. The company said its total volume of 1.59 million units for the quarter was 3% higher as compared to the third quarter of 2023.
CSX shares dipped 5.4% to $33.55 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>ProQR Therapeutics N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRQR#NASDAQ">PRQR</a>) shares dipped 16.2% to $3.37 in pre-market trading after surging 122% on Wednesday.</li>
<li>Lucid Group, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) declined 14.6% to $2.80 in pre-market trading after the company announced a public offering of common stock, along with a corresponding investment by an affiliate of the Public Investment Fund.</li>
<li>Lilium N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LILM#NASDAQ">LILM</a>) shares fell 13.2% to $0.6350 in pre-market trading.</li>
<li>Capricor Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) shares fell 10.6% to $18.33 in pre-market trading. The company commenced its public offering of common stock.</li>
<li>Cerus Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares fell 8.8% to $1.64 in pre-market trading after the company provided updates on its INTERCEPT red blood cell programs in the US and Europe.</li>
<li>KE Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NASDAQ">BEKE</a>) shares declined 7.7% to $20.23 in pre-market trading after gaining around 5% on Wednesday.</li>
<li>MINISO Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNSO#NASDAQ">MNSO</a>) shares fell 6.4% to $15.41 in pre-market trading.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) shares fell 5.4% to $4.22 in pre-market trading following downbeat third-quarter results. </li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41366043/wall-streets-most-accurate-analysts-give-their-take-on-3-consumer-stocks-delivering-high-dividend-yi">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Consumer Stocks Delivering High-Dividend Yields</a></li>
</ul>

Pre-Market Outlook

Movers

Trading Ideas

BEKE

CERS

LCID

LILM

MNSO

PRQR

CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

Capricor Therapeutics shares are trading lower. The company commenced its public offering of common stock.

The gross proceeds from the offering are expected to be approximately&nbsp;$75 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Capricor and assuming no exercise of the underwriters&#39; option.

Offerings

Capricor Therapeutics Prices Public Offering Of 4.412M Shares Of Common Stock At $17.00 Per Share

<h3>Gainers</h3>
<ul>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) stock increased by 189.2% to $0.94 during Wednesday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 21.72% to $0.68. The company's market cap stands at $14.5 million. </li>
<li>Chromocell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CHRO#AMEX">CHRO</a>) shares moved upwards by 12.23% to $1.0. The market value of their outstanding shares is at $5.7 million. </li>
<li>Nuvectis Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVCT#NASDAQ">NVCT</a>) shares moved upwards by 5.9% to $6.99. The market value of their outstanding shares is at $130.3 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) stock rose 5.17% to $18.5. The company's market cap stands at $117.3 million. </li>
<li>Ovid Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OVID#NASDAQ">OVID</a>) shares moved upwards by 5.08% to $1.24. The company's market cap stands at $88.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares fell 14.8% to $0.54 during Wednesday's after-market session. The company's market cap stands at $20.4 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares decreased by 12.74% to $7.33. The market value of their outstanding shares is at $106.4 million. </li>
<li>Capricor Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAPR#NASDAQ">CAPR</a>) stock decreased by 11.07% to $18.24. The company's market cap stands at $644.5 million. </li>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock decreased by 10.98% to $5.76. The company's market cap stands at $5.9 million. </li>
<li>Carmell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) shares declined by 10.4% to $0.56. The company's market cap stands at $11.7 million. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) shares declined by 9.45% to $1.63. The market value of their outstanding shares is at $302.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASMB

ATNF

BDRX

CHRO

CTCX

HCWB

KLTO

MTEM

NVCT

OVID

12 Health Care Stocks Moving In Wednesday's After-Market Session

Capricor Therapeutics Commences Public Offering Of Common Stock; Terms Not Disclosed

Capricor Therapeutics May Offer And Sell Up To $150M In Common Stock, Preferred Stock, Debt Securities, Warrants, And Units In One Or More Offerings

Reports Q3 revenue $2.3M, consensus $3.57M. Cash, cash equivalents and marketable securities totaled approximately $85.0M as of September 30, 2024 ...

Capricor Therapeutics reports Q3 EPS (38c), consensus (36c)

Capricor Therapeutics, Inc. (CAPR) Q3 2024 Earnings Call Transcript

Capricor Therapeutics, Inc. ( ($CAPR) ) has released its Q3 earnings. Here is a breakdown of the information Capricor Therapeutics, Inc. presented ...

Capricor Therapeutics Advances with Strategic Expansions

Joseph Pantginis, an analyst from H.C. Wainwright, reiterated the Buy rating on Capricor Therapeutics (CAPR – Research Report). The associated pric...

Capricor Therapeutics: Strategic Positioning and Financial Stability Drive Buy Rating

Today's macro environment reflects a strong risk-on sentiment, fueled by a notable rally in Bitcoin, which has surged past the $90,000 threshold.

Space, Biotech, And More: Today's Hottest Stocks To Watch

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Capricor Therapeutics (CAPR – Research Report). The associated price targ...

Capricor Therapeutics: Promising Developments and Strong Financial Position Drive Buy Rating

JonesResearch initiated coverage of Capricor Therapeutics (CAPR) with a Buy rating and $40 price target Capricor's lead asset is deramiocel, a muta...

Capricor Therapeutics initiated with a Buy at JonesResearch

Capricor Therapeutics (CAPR) announced that the European Medicines Agency, EMA, has granted both Orphan Drug and Advanced Therapy Medicinal Product...

Capricor Therapeutics granted ODD, ATMP status for deramiocel by EMA

Capricor wins key EU designations for the lead asset

In a report released today, Leland Gershell from Oppenheimer maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report), with a pric...

Oppenheimer Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)

ASTS

LUNR

Press Releases

Capricor Therapeutics to Present Long-Term Data from HOPE-2 Open Label Extension Study at 2024 World Muscle Society Congress

Capricor Therapeutics Announces Initiation of Rolling Submission of Biologics License Application (BLA) with U.S. FDA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy

Health Care

Capricor Therapeutics Announces Positive Long-Term Data from HOPE-2 OLE Study in Duchenne Muscular Dystrophy at 2024 World Muscle Society Congress

Financing

Capricor Therapeutics Announces Proposed Public Offering of Common Stock

Capricor Therapeutics Announces Pricing of Approximately $75 Million Public Offering of Common Stock

Capricor Therapeutics Announces Closing of Underwritten Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Capricor Therapeutics to Present Third Quarter 2024 Financial Results and Recent Corporate Update on November 13

Capricor Therapeutics to Present Exosome Platform Updates at 2024 American Association of Extracellular Vesicles Annual Meeting

Capricor Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

Capricor Therapeutics Granted Orphan Drug and ATMP Status for Deramiocel by European Medicines Agency

Applied Therapeutics, Inc. - Common Stock

Applied Therapeutics

Autolus Therapeutics plc - American Depositary Shares

Autolus Therapeutics

Comments

Capricor Therapeutics

뉴스

에 대한 최신 뉴스 Capricor Therapeutics (NASDAQ:CAPR) 주식

수요일, 9월 25, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌